Nantahala Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Nantahala Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-197,615	Closed	-$865K	–	126
2020 Q3	$865K	Sell	197,615 -75,723	-28%	-$662K	0.03%	105
2020 Q2	$2.52M	Hold	273,338	–	–	0.08%	98
2020 Q1	$3.97M	Buy	273,338 +22,892	+9%	+$497K	0.15%	78
2019 Q4	$2.96M	Buy	250,446 +30,442	+14%	+$510K	0.09%	78
2019 Q3	$5.54M	Buy	220,004 +92,609	+73%	+$2.67M	0.21%	68
2019 Q2	$3.24M	Buy	+127,395	New	+$4.93M	0.1%	84

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's VIRX Position: Q4 2020 in Review

Nantahala Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2020, closing a stake of 197,615 shares — an estimated $865K sold.

Nantahala Capital Management first reported a position in VIRX in Q2 2019 and held it in 6 quarters. The position peaked at $5.54M in Q3 2019. 33 funds tracked by Wall St. Rank hold VIRX as of Q4 2020.

Nantahala Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Nantahala Capital Management sold 197,615 Viracta Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $865K.
Nantahala Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Nantahala Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $5.54M in Q3 2019.
33 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Nantahala Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.